Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Learning objectives

This section has been developed as a resource providing information on poly (ADP-ribose) polymerase (PARP) inhibitors in prostate cancer.

Information included in this section is compiled from review of the medical literature and expert guidance from Elena Castro (Spanish National Cancer Research Center, Madrid, Spain), Alexander Wyatt (University of British Columbia, British Columbia, Canada), Gerhardt Attard (University College London, United Kingdom) and Steven Joniau (University Hospitals Leuven, Belgium).

Acknowledgements

Further information on PARP activity and inhibition can be found by clicking on each topic below.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings